Retrospective analysis of clinical results and predictors of response in chemo-na�ve patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy

Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer

“…Some recent studies have investigated potential predictors of tumor response in gastric cancer. A recent retrospective study of 119 patients with advanced or recurrent gastric cancer treated with S‐1 demonstrated that pretreatment variables such as hemoglobin level and the presence of lymph node metastasis were related to the response 14. Ajani et al demonstrated that clinical parameters such as TNM staging, tumor location, histological type, age and sex are unable to predict tumor regression in gastric cancer patients treated with paclitaxel‐based chemoradiotherapy 15, however, the tumor response associated factors were not totally documented in their study.…”

Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer

“…Pre-treatment hemoglobin level and the presence of LN involvement were found to be related with histopathological response in a retrospective study of 119 gastric cancer patients treated with single-agent NAC(S1)[41]. Another study suggested TNM staging, histological type, tumor location, sex and age were correlated with histopathological response[27], however, the tumor regression related factors were not fully investigated in this study.…”

Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥75years with impaired performance status

“…Fluoropyrimidines may be considered a reference treatment for elderly patients with advanced gastric cancer, and most studies investigating these agents as monochemotherapy suggest that approximately 20% of patients are progression-free 6 months after treatment onset. [25][26][27][28] The hypothesis for the current study was that, using FOLFOX-4 as induction chemotherapy and LV/bolus and continuous infusion 5-FU as maintenance chemotherapy, at least 40% of patients would be progression-free 6 months after the start of chemotherapy. It was calculated that 33 patients should be recruited with a 0.05 level of significance and 80% power for correct selection of treatment (absolute difference in 6-month DCR of 20%), based on Simon's mimax design.…”